secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2022-02-23T23:59:59+00:00
Accession:  0001193125-22-050077
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q4 revenue $38.9M (+27% YoY); FY2021 revenue $128M (+38%); guides FY2022 $160-168M
--------------------------------------------------------------------------------

- Q4 2021 revenue $38.9M (+27% YoY); FY2021 revenue $128.0M (+38% YoY).
- Q4 net income $0.3M (vs $5.6M in Q4 2020); FY net income $4.4M (vs $19.4M in 2020).
- Adjusted EBITDA Q4 $5.5M; FY $17.5M, up from $15.4M in 2020.
- Installed base 1,110 instruments; 453 instrument placements in FY2021.
- FY2022 revenue guidance $160-168M, representing 25-31% growth over FY2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312522050077/0001193125-22-050077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312522050077/d305036d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-050077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer